Department of Psychiatry, Austin Hospital, University of Melbourne, Heidelberg, Victoria, AUSTRALIA.
Expert Opin Pharmacother. 2021 Jun;22(9):1087-1097. doi: 10.1080/14656566.2021.1900826. Epub 2021 Mar 23.
: Major depressive disorder (MDD) remains one of the most prevalent mental health conditions. It is a chronic, relapsing condition and despite multiple treatment options, many patients fail to achieve remission of symptoms. Inadequacy of treatment has stimulated the search for agents with significant therapeutic advantages.: This review examines literature concerning the use of desvenlafaxine in the treatment of MDD published since a previous analysis in this journal in 2014. Published papers were identified via a PubMed and Web of Science search and excluded congress presentations. Results from clinical trials in MDD, systematic reviews, and post hoc analyses in patient subgroups, are reviewed.: Desvenlafaxine was an effective antidepressant with favorable safety and tolerability in adults. Efficacy was demonstrated in the subgroup of peri- and post-menopausal women with MDD but not in children and adolescents. There is a relatively low potential for drug-drug interactions due to its metabolic profile. Hepatic impairment does not significantly alter dose requirements, whereas severe renal disease requires some adjustments of dose. Desvenlafaxine maybe suitable in patients with comorbid physical illnesses. Desvenlafaxine can be a first line consideration for the treatment of cases of MDD uncomplicated by medical comorbidities.
重度抑郁症（MDD）仍然是最常见的心理健康问题之一。它是一种慢性、复发性疾病，尽管有多种治疗选择，但许多患者的症状仍未缓解。治疗不足促使人们寻找具有显著治疗优势的药物。
本综述检查了自 2014 年本刊上一篇分析以来发表的关于用去甲文拉法辛治疗 MDD 的文献。通过 PubMed 和 Web of Science 搜索确定了已发表的论文，并排除了会议报告。综述了 MDD 临床试验、系统评价和患者亚组事后分析的结果。
去甲文拉法辛是一种有效的抗抑郁药，在成年人中具有良好的安全性和耐受性。在患有 MDD 的绝经前和绝经后妇女亚组中显示出疗效，但在儿童和青少年中没有。由于其代谢特征，药物相互作用的潜力相对较低。肝功能损害不会显著改变剂量要求，而严重的肾脏疾病则需要调整剂量。去甲文拉法辛可能适用于伴有合并躯体疾病的患者。去甲文拉法辛可能是治疗无合并躯体疾病的 MDD 的一线药物。
